KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Edward A Stadtmauer, Keith M Sullivan, Mohamed El Idrissi, Bruno Salaun, Aránzazu Alonso Alonso, Charalambos Andreadis, Veli-Jukka Anttila, Adrian Jc Bloor, Raewyn Broady, Claudia Cellini, Antonio Cuneo, Alemnew F Dagnew, Emmanuel Di Paolo, HyeonSeok Eom, Ana Pilar González-Rodríguez, Andrew Grigg, Andreas Guenther, Thomas C Heineman, Isidro Jarque, Jae-Yong Kwak, Alessandro Lucchesi, Lidia Oostvogels, Marta Polo Zarzuela, Anne E Schuind, Thomas C Shea, Ulla Marjatta Sinisalo, Filiz Vural, Lucrecia Yáñez San Segundo, Pierre Zachée, Adriana Bastidas

Hum Vaccin Immunother 17(11) 4144-4154

PMID34406911
PMCIDPMC8828160
DOI10.1080/21645515.2021.1953346
发表日期2021-08-18
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

Immunocompromised individuals, particularly autologous hematopoietic stem cell transplant (auHSCT) recipients, are at high risk for herpes zoster (HZ). We provide an in-depth description of humoral and cell-mediated immune (CMI) responses by age (protocol-defined) or underlying disease (post-hoc) as well as efficacy by underlying disease (post-hoc) of the adjuvanted recombinant zoster vaccine (RZV) in a randomized observer-blind phase III trial (ZOE-HSCT, NCT01610414). 1846 adult auHSCT recipients were randomized to receive a first dose of either RZV or placebo 50-70 days post-auHSCT, followed by the second dose at 1-2 months (M) later. In cohorts of 114-1721 participants, at 1 M post-second vaccine dose: Anti-gE antibody geometric mean concentrations (GMCs) and median gE-specific CD4[2+] T-cell frequencies (CD4 T cells expressing ≥2 of four assessed activation markers) were similar between 18-49 and ≥50-year-olds. Despite lower anti-gE antibody GMCs in non-Hodgkin B-cell lymphoma (NHBCL) patients, CD4[2+] T-cell frequencies were similar between NHBCL and other underlying diseases. The proportion of polyfunctional CD4 T cells increased over time, accounting for 79.6% of gE-specific CD4 T cells at 24 M post-dose two. Vaccine efficacy against HZ ranged between 42.5% and 82.5% across underlying diseases and was statistically significant in NHBCL and multiple myeloma patients. In conclusion, two RZV doses administered early post-auHSCT induced robust, persistent, and polyfunctional gE-specific immune responses. Efficacy against HZ was also high in NHBCL patients despite the lower humoral response.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。